Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Biovica International AB (publ)
  6. News
  7. Summary
    BIOVIC B   SE0008613731

BIOVICA INTERNATIONAL AB (PUBL)

(BIOVIC B)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Biovica International : DiviTum«TKa in early treatment resistance trial

01/18/2021 | 02:00am EDT

DiviTum®TKa has been selected to be included in the new prospective clinical study TIRESIAS, with the aim of investigating if DiviTum®TKa can be used to identify early resistance to treatment by a CDK4/6 inhibitor in combination with an aromatase inhibitor in breast cancer patients.

TIRESIAS is a multi-center study that will collect samples from 150 patients with hormone receptor positive metastatic breast cancer who receive the first-line standard treatment: a CDK4/6 inhibitor and an aromatase inhibitor. The aim is to demonstrate that DiviTum®TKa can predict progression free survival and clinical benefit from samples taken as early as two weeks into treatment.

“Our study aims to show that the use of DiviTum®TKa as early as two weeks into therapy, can predict treatment response and also early identify treatment resistance. We have previously studied DiviTum®TKa in this setting and documented its ability to predict outcome of CDK4/6 inhibitors, and we look forward to the results of this prospective study designed to bring important clinical data to the medical community for clinical use of DiviTum®TKa for these patients,” said Dr. Luca Malorni, Prato Hospital and Principal Investigator of the study.

“About one out of seven metastatic breast cancer patients starting this type of treatment receive virtually no benefit from the therapy. Today, evidence that the therapy is not working is often not seen until three to six months into treatment, which is unfortunate. We are excited that DiviTum®TKa will be a part of a study that may point the way toward an improvement in the current standard of care,” said Anders Rylander, CEO of Biovica.

Link to study https://www.clinicaltrials.gov/ct2/show/NCT04660435

© Modular Finance, source Nordic Press Releases

All news about BIOVICA INTERNATIONAL AB (PUBL)
06/30BIOVICA INTERNATIONAL AB : – Annual report for the financial year 2020/202..
AQ
06/17BIOVICA INTERNATIONAL : Year-end Report February-April 2020/2021
AQ
06/17Biovica International AB Publ Reports Earnings Results for the Fourth Quarter..
CI
06/11BIOVICA INTERNATIONAL : - Premium potential
AQ
05/22BIOVICA INTERNATIONAL : Capital Markets Day invitation June 9
AQ
05/20BIOVICA INTERNATIONAL : DiviTumTKa shows strong capabilities in malignant melano..
AQ
05/20Biovica’S Divitumtka Shows Strong Capabilities in Malignant Melanoma
CI
04/29BIOVICA INTERNATIONAL : strengthens the management team
AQ
04/29Biovica Announces Management Appointments
CI
04/23BIOVICA INTERNATIONAL : DiviTum«TKa budget impact model results show potential f..
AQ
More news
Financials
Sales 2022 39,0 M 4,52 M 4,52 M
Net income 2022 -28,0 M -3,25 M -3,25 M
Net cash 2022 90,0 M 10,4 M 10,4 M
P/E ratio 2022 -55,7x
Yield 2022 -
Capitalization 1 529 M 177 M 177 M
EV / Sales 2022 36,9x
EV / Sales 2023 21,6x
Nbr of Employees 20
Free-Float 41,9%
Chart BIOVICA INTERNATIONAL AB (PUBL)
Duration : Period :
Biovica International AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 2
Last Close Price 55,10 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Anders Rylander Chief Executive Officer & Director
Cecilia Driving CFO, Head-Human Resource, IR & EVP
Lars Erik Holmqvist Chairman
Mattias Bergqvist Director-Clinical Development
Otti Bengtsson Gref Director-Research & Development
Sector and Competitors